T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.15% |
| 2 | Healthcare | 16.26% |
| 3 | Consumer Discretionary | 15.34% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
BridgeBio Pharma
BBIO
$15.5B
| $2.08M | ﹤0.01% |
44,493
-498,672
| -92% | -$26.7M |
|
1702
Toll Brothers
TOL
$13.9B
| $2.08M | ﹤0.01% |
37,692
-3,218
| -8% | -$190K |
|
1703
Integra LifeSciences
IART
$1.39B
| $2.07M | ﹤0.01% |
30,238
+1,551
| +5% | +$110K |
|
1704
BOK Financial
BOKF
$8.86B
| $2.06M | ﹤0.01% |
23,055
-244
| -1% | -$20.9K |
|
|
FRBK
1705
DELISTED
Republic First Bancorp Inc
FRBK
| $2.06M | ﹤0.01% |
670,392
-354,300
| -35% | -$1.23M |
|
|
VNE
1706
DELISTED
Veoneer, Inc.
VNE
| $2.06M | ﹤0.01% |
60,544
-7,900
| -12% | -$251K |
|
1707
Bank of Hawaii
BOH
$3.15B
| $2.06M | ﹤0.01% |
25,067
+85
| +0.3% | +$7.04K |
|
|
BCPC
1708
Balchem Corp
BCPC
$5.62B
| $2.06M | ﹤0.01% |
14,177
+1,198
| +9% | +$162K |
|
1709
Unum
UNM
$14.7B
| $2.05M | ﹤0.01% |
81,763
-271,911
| -77% | -$7.2M |
|
1710
Itron
ITRI
$4.51B
| $2.04M | ﹤0.01% |
26,952
-770
| -3% | -$66K |
|
1711
Olin
OLN
$2.2B
| $2.04M | ﹤0.01% |
42,185
-2,164
| -5% | -$101K |
|
1712
Avient
AVNT
$4.21B
| $2.03M | ﹤0.01% |
43,882
-847
| -2% | -$40.7K |
|
1713
QuantumScape Corp
QS
$3.87B
| $2.03M | ﹤0.01% |
82,731
+35,821
| +76% | +$818K |
|
1714
Sabra Healthcare REIT
SBRA
$5.12B
| $2.02M | ﹤0.01% |
137,532
-1,306
| -0.9% | -$22.1K |
|
1715
Beam Therapeutics
BEAM
$2.67B
| $2.02M | ﹤0.01% |
23,193
-2,691
| -10% | -$270K |
|
1716
JFrog
FROG
$11.8B
| $2.01M | ﹤0.01% |
60,009
+35,101
| +141% | +$1.41M |
|
1717
Hecla Mining
HL
$12.5B
| $2.01M | ﹤0.01% |
365,100
+22,000
| +6% | +$137K |
|
1718
Bank OZK
OZK
$5.69B
| $2M | ﹤0.01% |
46,535
+887
| +2% | +$37K |
|
1719
Black Hills Corp
BKH
$5.64B
| $1.99M | ﹤0.01% |
31,779
-4,730
| -13% | -$322K |
|
1720
Coastal Financial
CCB
$776M
| $1.99M | ﹤0.01% |
+62,358
| New | +$1.86M |
|
1721
Crane NXT
CXT
$2.93B
| $1.98M | ﹤0.01% |
60,237
+2,228
| +4% | +$74.2K |
|
1722
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $1.98M | ﹤0.01% |
4,611
-154
| -3% | -$67.9K |
|
1723
UMB Financial
UMBF
$11.5B
| $1.97M | ﹤0.01% |
20,413
+50
| +0.2% | +$4.56K |
|
1724
O-I Glass
OI
$1.03B
| $1.96M | ﹤0.01% |
137,631
-7,509
| -5% | -$112K |
|
1725
Celsius Holdings
CELH
$7.41B
| $1.96M | ﹤0.01% |
65,364
+8,451
| +15% | +$217K |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.